

\*\*\*\*Published September 2016\*\*\*\*

## MarketVIEW: Cholera vaccines (CAT: VAMV069)

<b>Product Name</b>	:	<b>MarketVIEW: Cholera vaccines</b>
<b>Description</b>	:	Vaccine opportunity assessment
<b>Contents</b>	:	Executive presentation (.pdf) + 2 commercial forecast model(s) (.xls)
<b>Therapeutic Area</b>	:	Bacterial/travel vaccines
<b>Publication date</b>	:	September 2016
<b>Catalogue No</b>	:	VAMV069

## Background

**Cholera** is a rapidly dehydrating diarrheal disease caused by the ingestion of *Vibrio cholera*. The infection is primarily linked to insufficient access to safe water and proper sanitation. Cholera causes a major burden of disease in Asia, sub-Saharan Africa and Hispaniola. Globally an estimated 2.86 million cholera cases occur annually in endemic countries causing 95,000 deaths. 1.3 billion people are believed to be at risk. Cholera is relatively rare in travellers to cholera-endemic countries.

Cholera vaccines are approved for use in travellers and endemic countries. Examples are Valneva's Dukoral (approved in Europe, Canada and Australia) and recently PaxVax's Vaxchora, now approved in the US (June 2016). For endemic use, the WHO maintains a stockpile where Dukoral, Shantha's Shanchol (India) and EuBiologics (South Korea) Euvichol are all WHO prequalified, but Shanchol is currently the only vaccine provided by the stockpile.

This **MarketVIEW** product is composed of two comprehensive MS Excel-based models + summary presentation that forecasts the potential commercial value of cholera travel vaccines across major Western markets of traveler origin<sup>1</sup> to 2030. Two scenarios are included based on the potential regulatory approval of **PaxVax's Vaxchora** outside the US market. Full traveler modelling assumptions are clearly indicated with a detailed build-up worksheet per country of origin. An up to date review of cholera epidemiology is also included along with some discussion of endemic use and other relevant topics.

---

<sup>1</sup> US, Canada, Australia, Finland, France, Germany, Italy, Norway, Spain, Sweden, the UK

## Methodology

**VacZine Analytics** has closely monitored all significant source material pertaining to cholera vaccines and novel vaccine approaches. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of bacterial/travel vaccines has also been utilised.

### PRODUCT CONTENTS:

**Published September 2016 (CAT No: VAMV069)**

\*\*\*\*This product is composed of [two forecast models \(.xls\)](#)<sup>2</sup> and [a summary presentation \(.pdf\)](#)<sup>3</sup>

Contents  
Author's note  
Executive summary  
Key commercial model outputs  
Cholera vaccines: commercial model – key outputs  
Global volume, all cholera travel vaccines, 2015-2030 (doses)  
Global sales by country, all cholera travel vaccines, 2015 & 2030 (\$m)  
Global sales by cholera vaccine, 2015-2030 (\$m)  
Global volume by cholera vaccine, 2015-2030 (doses)  
Global sales by vaccine and country, 2030, (\$m)  
Dukoral and Vaxchora - sales/volume per region in 2020  
Vaxchora: scenario based forecast to 2030 (\$m & doses)  
Cholera vaccines: endemic versus travel use, 2016  
Cholera vaccines: commercial model assumptions  
Commercial model overview  
Trips to endemic countries (*4 slides*)  
Modelling assumptions: Pre-travel health behaviour  
Dukoral geographic sales breakdown, 2014  
Uptake rates of commonly used travel vaccines  
Pre-travel behaviour and cholera vaccine uptake, 2016 and 2030  
Pricing and market share assumptions  
Cholera vaccines: market drivers and resistors  
Disease background and epidemiology  
The pathogen  
Clinical features and treatment  
Epidemiology: overview  
Epidemiology: cases reported to WHO by region, 1989-2014  
Epidemiology: areas reporting cholera outbreaks, 2010-2014  
Travel-associated cholera  
Travel-associated cholera: cases by source 2001-2011, US  
Cholera vaccines: approved products

<sup>2</sup> Model contents available upon application

<sup>3</sup> Presentation titles may apply to more than one slide

**Continued.....**

Cholera vaccines: Dukoral (Valneva)  
Dukoral: approval history  
Dukoral: reported sales  
Dukoral: label change (Canada)  
Dukoral: Canada marketing campaign  
Cholera vaccines: PaxVax – Vaxchora  
Vaxchora: challenge studies  
Vaxchora: regulatory outlook  
Vaxchora: ex-US filings  
Comparison of cholera vaccines available for the travel market  
Cholera vaccines used in endemic settings (*2 slides*)  
Backup/methodology slides  
Cholera vaccine recommendations for travellers (*3 slides*)  
Pre-travel behaviour assumptions  
Bibliography  
Disclaimer  
About **VacZine Analytics**

**Slide number = 61**

## PRODUCT COST:

**VacZine Analytics** will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$9995.00**/ GBP **£7690.00**<sup>#</sup> (Region license)\*
- PRESENTATION ONLY - **\$6995**/ GBP **£5425**<sup>#</sup> (Region license)\*

<sup>#</sup> Indicative company rate only. Prevailing rate applied to date of transaction.

\*A region is North America, Europe or ROW

For orders in the UK, VAT at 20.0% will be added to final invoice total

*Agency/consultancy rates (commercial use) are available upon request*

## HOW TO ORDER:

To order please contact your region account manager or order direct at [orders@vaczine-analytics.com](mailto:orders@vaczine-analytics.com)

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics (R)** and the “spiral logo” are UK Registered Trademarks, 2009

## BIBLIOGRAPHY

1. WHO. Global Health Observatory (GHO) data. Number of reported cholera cases. Available at: [http://www.who.int/gho/epidemic\\_diseases/cholera/cases/en/](http://www.who.int/gho/epidemic_diseases/cholera/cases/en/). Accessed August 2016
2. World Tourism Organisation (WTO). Available at: <http://www.e-unwto.org>. Accessed August 2016
3. Heywood AE et al. A cross-sectional study of pre-travel health-seeking practices among travelers departing Sydney and Bangkok airports. *BMC Public Health*. 2012 May 2;12:321.
4. Pavli A et al. Vaccinations for international travellers travelling from Greece. *Travel Med Infect Dis*. 2013 Jul-Aug;11(4):225-30.
5. Valneva SE presents its FY financial results 2014. Analyst Presentation March 20, 2015.
6. Cucchi A et al. [Travellers' compliance with the use of an oral cholera vaccine]. *Ig Sanita Pubbl*. 2010 Jul-Aug;66(4):409-18.
7. DUKORAL Prescribing information. March 2016. Available at: [http://www.valnevauk.com/wp-content/uploads/2016/02/UKDUK03160006-DUKORAL-UK-Prescribing-Information-March-2016\\_FV2-VAL1003.pdf](http://www.valnevauk.com/wp-content/uploads/2016/02/UKDUK03160006-DUKORAL-UK-Prescribing-Information-March-2016_FV2-VAL1003.pdf). Accessed August 2016
8. CDC. Adult Vaccine Price List. Available at: <http://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/>. Accessed August 2016
9. Wong K. Centers for Disease Control and Prevention. Cholera in US Travelers. Advisory Committee on Immunization Practices (ACIP). Summary Report October 21, 2015 Atlanta, Georgia.
10. WHO. Weekly epidemiological record. Cholera, 2014. October 2015. No. 40, 2015, 90, 517–544.
11. WHO. Cholera. Available at: <http://www.who.int/cholera/en/>. Accessed September 2016.
12. Ali M et al. Updated global burden of cholera in endemic countries. *PLoS Negl Trop Dis*. 2015 Jun 4;9(6)
13. WHO. Global Health Observatory (GHO) data. Available at: [http://www.who.int/gho/epidemic\\_diseases/cholera/cases\\_text/en/](http://www.who.int/gho/epidemic_diseases/cholera/cases_text/en/). Accessed August 2016.
14. International Coordinating Group oral cholera vaccine annual meeting report 2015. 11-12 June 2015 – Geneva, Switzerland. Available at: [www.who.int/cholera/vaccines/Final\\_OCV\\_ICG\\_Meeting\\_report\\_June15.pdf](http://www.who.int/cholera/vaccines/Final_OCV_ICG_Meeting_report_June15.pdf). Accessed August 2016.
15. WHO. Areas affected by cholera epidemics (Feb 2016). Available at: [http://www.who.int/gho/epidemic\\_diseases/cholera/epidemics/en/](http://www.who.int/gho/epidemic_diseases/cholera/epidemics/en/). Accessed August 2016
16. Mahon BE et al. Reported cholera in the United States, 1992-1994: A reflection of global changes in cholera epidemiology. *JAMA* 1996; 276(4):307-312.
17. Wittlinger F et al. Risk of cholera among Western and Japanese travelers. *Journal of Travel Medicine* 1995; 2:154-158.
18. Loharikar A et al. Cholera in the United States, 2001-2011: a reflection of patterns of global epidemiology and travel. *Epidemiol Infect*. 2015 Mar;143(4):695-703
19. Dukoral suspension SPC. Last Updated on eMC 07-Dec-2015. Available at: <https://www.medicines.org.uk/emc/medicine/31272>. Accessed August 2016.
20. Canadian Immunization Guide. Cholera and Enterotoxigenic Escherichia Coli (ETEC) Travellers' Diarrhea vaccine. Available at: <http://www.phac-aspc.gc.ca/publicat/cig-gci/p04-cho-eng.php>. Accessed August 2016
21. Valneva. 2015 Annual Business Report
22. Valneva – a leading pure play and independent vaccine company. Company Presentation July 2016
23. Valneva provides update on DUKORAL vaccine in Canada. December 2015. Available at: [https://www.valneva.com/download.php?dir=News\\_2015&file=2015\\_12\\_23\\_Valneva\\_Dukoral\\_HC\\_PR\\_EN.pdf](https://www.valneva.com/download.php?dir=News_2015&file=2015_12_23_Valneva_Dukoral_HC_PR_EN.pdf). Accessed August 2016.
24. Dukoral. Available at: <https://www.dukoralcanada.com/>. Accessed August 2016
25. Chen WH et al. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With *Vibrio cholerae* O1 El Tor. *Clin Infect Dis*. 2016 Jun 1;62(11):1329-35.
26. Wong K. Cholera vaccine update and proposed recommendations. Advisory Committee on Immunization Practices Meeting. 22 June 2016.
27. PaxVax Announces Primary Endpoints Met in Phase 3 Cholera Vaccine Trial. December 2014. Available at: [www.paxvax.com/sites/default/files/vaxchora\\_l2l\\_ph3\\_press\\_release\\_final\\_12.8.14.pdf](http://www.paxvax.com/sites/default/files/vaxchora_l2l_ph3_press_release_final_12.8.14.pdf). Accessed August 2016.
28. EMEA. Cholera vaccine. Public summary of the evaluation of the proposed paediatric investigation plan. EMA/507469/2014.
29. Anh DD et al. Oral cholera vaccine development and use in Vietnam. *PLoS Med*. 2014 Sep 2;11(9)
30. Desai SN et al. A second affordable oral cholera vaccine: implications for the global vaccine stockpile. *Lancet Glob Health*. 2016 Apr;4(4):e223-4.
31. WHO. The Use of Oral Cholera Vaccines for International Workers and Travelers to and from Cholera-Affected Countries. 13 January 2016. Available at: [http://www.who.int/cholera/vaccines/OCV\\_use\\_International\\_Workers\\_Travelers\\_Technical\\_Note\\_13Jan2016.pdf](http://www.who.int/cholera/vaccines/OCV_use_International_Workers_Travelers_Technical_Note_13Jan2016.pdf). Accessed August 2016

32. Cholera - Vaccination. Available at: <http://www.nhs.uk/Conditions/Cholera/Pages/Vaccination.aspx>. Accessed August 2016
33. The Australian Immunisation Handbook 10th Edition. 4.1 Cholera. Available at: <http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home~handbook10part4~handbook10-4-1#4.1.7> Accessed August 2016
34. Canadian Immunization Guide. April 2014 .
35. Nickonchuk T et al. Oral cholera vaccine for traveler's diarrhea prophylaxis. *Can Fam Physician*. 2014 May;60(5):451
36. Hamer DH et al. Travel health knowledge, attitudes and practices among United States travelers. *J Travel Med*. 2004 Jan-Feb;11(1):23-6.
37. Yanni EA et al. Knowledge, attitudes, and practices of US travelers to Asia regarding seasonal influenza and H5N1 avian influenza prevention measures. *J Travel Med*. 2010 Nov-Dec;17(6):374-81.
38. Van Herck K et al. Knowledge, attitudes and practices in travel-related infectious diseases: the European airport survey. *J Travel Med*. 2004 Jan-Feb;11(1):3-8
39. Lopez-Velez R et al. Spanish travelers to high-risk areas in the tropics: airport survey of travel health knowledge, attitudes, and practices in vaccination and malaria prevention. *J Travel Med*. 2007 Sep-Oct;14(5):297-305.
40. Schunk M et al. Vaccination status and prophylactic measures of travelers from Germany to subtropical and tropical areas: results of an airport survey. *J Travel Med*. 2001 Sep-Oct;8(5):260-2.

**TERMS and CONDITIONS:**

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

**VacZine Analytics**

Warren House  
Bells Hill  
Bishops Stortford  
Herts  
CM23 2NN  
United Kingdom  
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926  
E-mail: [info@vacZine-analytics.com](mailto:info@vacZine-analytics.com)

## About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics (R)** and "the spiral logo" are UK Registered Trademarks, 2009